Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study
Amar Vedamurthy, Nikitha Gangasani, Ashwin N. Ananthakrishnan
Topics & Concepts
MedicineVedolizumabCancerInternal medicineUlcerative colitisInflammatory bowel diseaseRetrospective cohort studyHazard ratioMalignancyColorectal cancerOncologyGastroenterologyDiseaseConfidence intervalInflammatory Bowel DiseaseMicroscopic ColitisLiver Diseases and Immunity